Healthcare provider profile · identity verified

Marisa Friscia, MD

Internal Medicine · MATTOON, IL · NPI 1568657328

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	524	144
Levothyroxine Sodium	Levothyroxine Sodium	372	77
Lisinopril	Lisinopril	349	93
Pantoprazole Sodium	Pantoprazole Sodium	250	70
Amlodipine Besylate	Amlodipine Besylate	226	63
Rosuvastatin Calcium	Rosuvastatin Calcium	189	49
Metoprolol Succinate	Metoprolol Succinate	172	45
Omeprazole	Omeprazole	166	45
Metformin Hcl	Metformin Hcl	161	45
Losartan Potassium	Losartan Potassium	158	47
Simvastatin	Simvastatin	152	39
Furosemide	Furosemide	146	42
Sertraline Hcl	Sertraline Hcl	146	36
Montelukast Sodium	Montelukast Sodium	127	28
Allopurinol	Allopurinol	115	29
Jardiance	Empagliflozin	109	28
Tamsulosin Hcl	Tamsulosin Hcl	109	32
Ezetimibe	Ezetimibe	96	27
Pravastatin Sodium	Pravastatin Sodium	96	22
Hydrochlorothiazide	Hydrochlorothiazide	94	26
Trazodone Hcl	Trazodone Hcl	92	22
Albuterol Sulfate Hfa	Albuterol Sulfate	91	31
Eliquis	Apixaban	91	16
Carvedilol	Carvedilol	88	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	87	21
Gabapentin	Gabapentin	84	24
Fluticasone Propionate	Fluticasone Propionate	79	38
Potassium Chloride	Potassium Chloride	70	19
Clopidogrel	Clopidogrel Bisulfate	67	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	65	16
Metoprolol Tartrate	Metoprolol Tartrate	65	18
Farxiga	Dapagliflozin Propanediol	61	13
Januvia	Sitagliptin Phosphate	60	suppressed
Duloxetine Hcl	Duloxetine Hcl	57	13
Famotidine	Famotidine	56	22
Tramadol Hcl	Tramadol Hcl	55	14
Finasteride	Finasteride	54	14
Citalopram Hbr	Citalopram Hydrobromide	50	13
Ozempic	Semaglutide	49	11
Alendronate Sodium	Alendronate Sodium	44	12
Synthroid	Levothyroxine Sodium	44	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Prednisone	Prednisone	41	31
Trulicity	Dulaglutide	41	suppressed
Warfarin Sodium	Warfarin Sodium	41	suppressed
Topiramate	Topiramate	40	12
Bupropion Xl	Bupropion Hcl	39	suppressed
Atenolol	Atenolol	37	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	36	suppressed
Lorazepam	Lorazepam	34	12
Pioglitazone Hcl	Pioglitazone Hcl	34	suppressed
Donepezil Hcl	Donepezil Hcl	33	suppressed
Dulera	Mometasone/Formoterol	33	suppressed
Meloxicam	Meloxicam	32	14
Breo Ellipta	Fluticasone/Vilanterol	31	suppressed
Ventolin Hfa	Albuterol Sulfate	31	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	30	24
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Valsartan	Valsartan	26	suppressed
Baclofen	Baclofen	25	suppressed
Irbesartan	Irbesartan	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	19
Nitroglycerin	Nitroglycerin	23	19
Clonazepam	Clonazepam	22	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Fluconazole	Fluconazole	21	14
Primidone	Primidone	21	suppressed
Mounjaro	Tirzepatide	20	suppressed
Meclizine Hcl	Meclizine Hcl	19	15
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Cephalexin	Cephalexin	18	14
Clonidine Hcl	Clonidine Hcl	18	suppressed
Repatha Sureclick	Evolocumab	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Methimazole	Methimazole	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Amoxicillin	Amoxicillin	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Methylprednisolone	Methylprednisolone	15	14
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Diazepam	Diazepam	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Modafinil	Modafinil	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Sucralfate	Sucralfate	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Dapsone	Dapsone	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error